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a b s t r a c t
The term vulnerable plaque has been established to describe an atherosclerotic lesion with a
high probability of causing a future coronary event [1,2]. The identiﬁcation and stabilization
of the lesion before its rupture may reduce the morbidity and mortality caused by coronary
artery disease. Modern imaging modalities such as computer tomography coronary angiog-
raphy, intravascular ultrasound, optical coherence tomography and near-infrared spectros-
copy have a potential in ﬁnding these vulnerable plaques. This raises opportunities in the
primary and secondary prevention of coronary artery disease. This review summarizes the
current knowledge with an emphasis put on the research advances in the ﬁeld of near-
infrared spectroscopy a modality that has been intentionally developed for the detection of
lipid-core plaques.
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All rights reserved.
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In the past decades it has been established that the
development of a vulnerable atherosclerotic plaque (VP) is
the initial step in the process leading directly to coronary
thrombosis. Plaque vulnerability was deﬁned functionally as
the susceptibility of a plaque to rupture [1]. It has been revealed
in autopsy studies that the non-thrombosed lesion that most
resembles the acute plaque rupture is the thin cap ﬁbroather-
oma (TCFA), which is characterized by a large necrotic core of
lipid and cellular debris and with an overlying ﬁbrous cap
measuring <65 mm, containing only rarely smooth muscle
cells but numerous macrophages [3]. Based on these patho-
logical ﬁndings it seems crucial to identify such high-risk
plaques in stable patients, with the ultimate goal of preventing
its rupture, thereby averting myocardial infarction and sudden
cardiac death [4]. The prospective clinical multicenter study
PROSPECT showed that lesions responsible for unanticipated
events are frequently angiographically mild. However, most of
them are thin-cap ﬁbroatheromas and can be characterized by
a large plaque burden, a small luminal area, or some
combination of these characteristics, as determined by gray-
scale and radiofrequency intravascular ultrasonography [5].
The results of the PREDICTION trial carried out by Stone et al.
proofed that not only large plaque burden, but also low local
endothelial shear stress can inﬂuence plaque progression
[6]. The above-mentioned characteristics identiﬁed by some
non-invasive or invasive imaging methods might help to
detect VP in high-risk patients. Near-infrared spectroscopy
(NIRS) imaging was developed explicitly for detection of a
lipid-core plaque (LCP) a believed clinical correlate of VP [4].
The hybrid catheter that contains near-infrared spectrosco-
py and intravascular ultrasound (NIRS-IVUS) can assess
plaque burden while simultaneously identifying LRP with
NIRS and therefore offers a unique possibility of combined
information about chemical composition and morphology of
the plaque.
Non-invasive methods – possibly an important tool
in primary prevention
Although non-invasive modalities are obviously the less
precise method of VP detection, a research in this ﬁeld is
particularly important as these techniques may help to
identify high-risk plaques in asymptomatic subjects without
the risks associated with an invasive procedure. Amongst the
non-invasive methods CT coronary angiography (CTA) seems
to be the most notable one. The presence of positive
remodeling, low attenuation plaque (LAP) and spotty calciﬁ-
cation were signiﬁcantly more frequent in the culprit acute
coronary syndrome (ACS) lesions in the study by Motoyama
et al. [7]. Furthermore, in asymptomatic patients, presence of
positive remodeling and LAP portends a greater risk fordevelopment of acute coronary events. However, CTA is not
indicated in the evaluation of most asymptomatic patients
given the risks of radiation burden. Primary prevention studies
are needed to evaluate the merit of plaque characterization
and to deﬁne the population that will beneﬁt the most from
such a strategy [4].
Invasive methods in vulnerable plaque imaging
The angiogram is still considered the ‘‘gold standard’’ for the
deﬁnition of coronary anatomy; although it is well recognized
that angiography signiﬁcantly underestimates the extent of
atherosclerosis [8]. Therefore, numerous invasive methods
have been evaluated to increase sensitivity and speciﬁcity of
atherosclerotic plaque detection. Some of them focus on the
microanatomy of a plaque (intravascular ultrasound – IVUS,
intravascular optical coherence tomography – OCT), some are
directed at measuring the metabolic activity of a plaque to
predict the risk of its disruption (intravascular thermography
and elastography), and ﬁnally some techniques rely on
measuring the chemical composition of a plaque (NIRS) [9–
11]. The most promising methods include IVUS, OCT and NIRS
[2].
Intravascular ultrasound
Between the above-mentioned methods, IVUS has a particular
role in the VP issue. It can visualize the external elastic lamina
of the vessel wall, allowing the determination of vessel size,
plaque burden and morphology [12]. Radiofrequency (RF)
analysis of the ultrasonic signal (virtual histology RF – IVUS)
permits further characterization of plaque composition, which
correlates well with histological analysis [13]. It is currently the
only method with a proven capability of identifying lesions
responsible for future major adverse cardiac events (MACE).
This has been conﬁrmed by prospective natural history
studies.
The most important of these studies is certainly the
pioneering PROSPECT trial. In this prospective study,
697 patients with ACS underwent three-vessel coronary
angiography, gray-scale and radiofrequency IVUS after percu-
taneous coronary intervention (PCI). Subsequent MACE (death
from cardiac causes, cardiac arrest, myocardial infarction, or
re-hospitalization due to unstable or progressive angina) were
adjudicated to be related to either originally treated (culprit)
lesions or untreated (non-culprit) lesions. The median follow-
up period was 3.4 years. About half of the subsequent MACE
were related to non-culprit lesions. The interesting fact was
that most non-culprit lesions responsible for follow-up events
were angiographically mild at baseline, but were more likely
than those not associated with recurrent events to be
characterized by a plaque burden of 70% or greater or a small
minimal luminal area or to be classiﬁed on the basis of RF-IVUS
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identifying a VP prior to the occurrence of MACE [5]. A number
of smaller studies have subsequently conﬁrmed these results.
These include the VIVA trial a prospective IVUS-virtual
histology (VH-IVUS) study where a total of 170 patients with
either ACS or stable coronary artery disease (CAD) underwent
three-vessel VH-IVUS scans pre-PCI. The presence of TCFA
was the only independent predictor of subsequent MACE in
this trial [14].
Optical coherence tomography
OCT is an intravascular catheter that uses light as a probe. This
offers a much greater axial resolution which is unfortunately
paid for by a lower penetrance into the vessel wall. OCT is
capable of identifying objects with the dimensions of about
10 mm. This makes it an excellent tool for visualization of a
thin ﬁbrous cap as well as studying the plaques' microanato-
my [15]. In fact the excellent resolution of OCT allows us to
measure the thickness of the ﬁbrous cap as well as quantifying
the amount of macrophages within the cap by ﬁbrous cap
macrophage density measurement [16]. A recently published
study by Kato et al. offers interesting results. This study used a
multicenter registry to compare 3 vessels OCT scans in
patients with ACS versus stable CAD. A total of 104 patients
were enrolled (17 ACS patients vs. 87 non-ACS patients). The
authors demonstrate that non-culprit lesions in patients with
ACS have more VP characteristics compared to non-ACS
patients [17].Fig. 1 – Coronarography and the corresponding near-infrared spe
of a stenosis of the left anterior descending artery (LAD) in a pa
intervention (PCI) of the right coronary artery (RCA) because of a
significant stenosis of LAD can be seen in panel A. A convention
supplemented by the additional information provided by NIRS (
the presence and location of lipids in the lesion. In the rectangu
lipid core located right in the place of the tightest stenosis (pane
the distance of the pullback within the artery whereas the width
The extent of the lipid core is quantified by the lipid-core burden
chemogram multiplied by 1000. The region with the highest lipid
index (mxLCBI) per 4 mm (panel C).Near-infrared spectroscopy
NIRS is a novel intravascular technique that has been
intentionally developed for the identiﬁcation of a lipid core
within an atherosclerotic lesion [18]. This is achieved by
determination of the lesion's chemical composition based on
different absorbance of the near-infrared spectra [19]. A hybrid
catheter that incorporates both NIRS and IVUS is currently
available (TVC Imaging Systém, InfraReDx INC., Burlington,
MA). An advantage of the NIRS-IVUS system is that it provides
us with structural (IVUS) and compositional (NIRS) informa-
tion in a single pullback [20]. This suggests a great potential for
this modality for identiﬁcation of high-risk plaques [8].
Unfortunately a limitation of NIRS is the penetrance into
the vessel wall. The majority of the NIRS tissue information is
obtained from a depth of 1 mm or less [21].
The results of NIRS are presented as a ‘‘chemogram’’ – a
color coded map that indicates the probability of LCP presence
in given locations. On the chemogram the X-axis indicates the
pullback position in millimeters and the Y-axis indicates the
circumferential position in degrees as if the coronary vessel
has been split open along its longitudinal axis. Each pixel on
the chemogram represents a probability of lipid presence at
the given region, that is color-coded on a red-to-yellow color
scale, with the low probability of lipid shown as red and the
high probability of lipid shown as yellow (Fig. 1C) [22].
The lipid-core burden index (LCBI) has been established for
quantiﬁcation of lipid presence in the scanned region. LCBI can
be viewed as the fraction of yellow pixels on the chemogramctroscopy and intravascular ultrasound (NIRS-IVUS) images
tient who recently underwent a percutaneous coronary
n ST-elevation myocardial infarction. An angiographically
al IVUS image of the stenosis, as shown in panel B, is
a color ring around the IVUS image). Yellow color indicates
lar NIRS chemogram of the lesion yellow color indicated a
l C, red arrow). The height of the chemogram represents
 represents rotation of the imaging element from 0 to 3608.
 index (LCBI). The LCBI is the fraction of yellow pixels on the
 burden is characterized by the maximal lipid-core burden
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(mxLCBI) per 4 mm is used. This describes the region with the
highest lipid burden. Additionally, the mean and maximal
angle of lipid core in the region of interest can be measured for
a better characteristic of the lesions' circumferential extent
[22,23]. An example of a chemogram and the corresponding
IVUS and angiography is provided in Fig. 1.
NIRS and vulnerable plaque imaging
The accuracy of catheter-based NIRS system to identify LCP
through blood was conﬁrmed in a prospective study of
coronary autopsy specimens made by Gardner et al. [23].
The feasibility of in vivo coronary LCP detection with
intravascular NIRS system was demonstrated in the SPECTACL
study, where spectral data were obtained safely and were
similar to those from autopsy specimens [21]. A study carried
out by Pu et al. found a positive relationship between virtual
histology derived necrotic-core percentage and NIRS derived
LCBI in non-calciﬁed plaques, but not in calciﬁed plaques [22].
It was shown in a porcine model (which demonstrates
complex, human-like coronary artery lesions) that the early
and persistent accumulation of lipid within the arterial wall
detected by NIRS leads to the subsequent development of
ﬁbroatheromas [24].
Although NIRS is still quite a new method the evidence
about its capabilities of detecting a VP in humans is increasing.
The differences between stable atherosclerotic lesions and
lesions with ACS have been studied. Indeed, NIRS conﬁrmed
in vivo a fact known from autopsy studies that lesions in ACS
patients more frequently harbor a lipid core. Furthermore, the
vessels in ACS patients commonly bare other LCP (an example
is provided in Fig. 1) and approximately one half of target
lesions in stable patients were composed of LCP. It can be
assumed that these are possible VP with a potential of causingFig. 2 – Coronarography and NIRS-IVUS imaging in the same pa
18 mm, Abbot Vascular, Temecula, CA, United States) was deplo
corresponding IVUS image is shown in panel B. The NIRS chemo
during the PCI. It can be assumed that the lipid-rich material em
decrease of both LCBI and mxLCBI (panel C).future coronary events [25]. A recently published study by
Madder et al. described a NIRS signature imprint of ST-
elevation myocardial infarction (STEMI) culprit lesions. In this
study NIRS was performed in 20 patients with acute STEMI.
Findings in culprit lesions were compared to observations in
non-culprit segments and in autopsy control segments.
Culprit and control segments were analyzed for the mxLCBI.
It was proven that the STEMI culprit lesions had signiﬁcantly
higher lipid content (5.8-fold higher mxLCBI than non-culprit
segments and 87-fold higher than control segments). The
authors established a threshold of mxLCBI >400 distinguished
STEMI culprit segments from specimens free of large LCP by
histology [26].
An interesting fact was published by Ali and his
colleagues. In their small study OCT and NIRS-IVUS were
used to detect neoatherosclerosis with high lipid content
and a thin-cap as a cause of late in-stent restenosis related
DES failure [27].
NIRS and optimization of PCI strategy
The distal embolization of plaque contents during PCI can
lead to slow or no-reﬂow and myocardial infarction (MI). It
was revealed that PCI of LCP-positive lesions as assessed by
NIRS is associated with an increased risk of MI after PCI. Thus,
NIRS may allow lesion-speciﬁc risk stratiﬁcation before PCI
and optimization of PCI strategies for myocardial injury risk
minimization [28]. The use of an embolic protection device
during PCI based on NIRS-IVUS information was studied in the
study by Brilakis et al. [29]. The signiﬁcant decrease of LCBI
after PCI has been observed and embolized material was
retrieved in eight of nine patients. Fig. 2 provides an example
of the reduction of LCP after stent deployment during PCI. The
NIRS-IVUS system also showed a potential in optimization of
stent length to cover the whole LCP [30,31] and to prevent stenttient after a biodegradable vascular scaffold (Absorb 3.5/
yed. Panel A shows a good angiographic result. The
gram indicates that the large lipid core almost disappeared
bolized during the procedure. This corresponds with a
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the association between NIRS detected pre-stenting LCPs and
post-stenting thrombus formation, as assessed by OCT. The
study suggested that stenting of large LCPs may be associated
with intrastent thrombosis. The authors suggest that this
ﬁnding of high frequency of thrombus formation post-stenting
of LCPs may be related to the increased thrombogenicity of LCP
exposed to the circulating blood during stenting and propose
that more intensive anticoagulant and/or antiplatelet therapy
may be beneﬁcial in such lesions [33]. A case report published
by Sakhuja et al. suggested that such events may occur when a
stent is placed within a LCP [32].
NIRS and vulnerable plaque stabilization
A study that evaluated the prognostic value of NIRS has been
recently published by Oemrawsingh et al. In this prospective
observational study non-culprit vessels of 203 patients with
either stable CAD or ACS referred for PCI were examined by
NIRS. The primary endpoint of the study (the composite of all-
cause mortality, non-fatal ACS, stroke and unplanned coro-
nary revascularization) occurred 4 times more often in
patients with a LCBI equal to or above the median value of
43 during a one-year follow-up [33].
The identiﬁcation of VP might enable targeted use of both
pharmacological agents and interventional techniques to
provide plaque stabilization. In the prospective YELLOW trial
87 patients, with diabetes mellitus (DM) and a multivessel CAD
with a lesion indicated for PCI and one other obstructive
(determined by fractional ﬂow reserve [FFR] measurement)
non-target lesion (NTL), were randomized to aggressive
(rosuvastatin 40 mg daily) or standard-of-care lipid lowering
therapy. The NTLs were evaluated for lipid content and plaque
morphology by NIRS-IVUS. After 7 weeks of therapy changes in
FFR, LCBI, and IVUS were documented. The results proved that
statin therapy reduces lipid content of a lesion thus suppos-
edly reducing the plaques vulnerability [34].
Clearly all the above-mentioned results have to be tested by
larger and more powerful studies. Two such studies have
already been initiated. The PROSPECT II trial will enroll 900
patients with ACS who are undergoing PCI for an initial culprit
lesion. Analogically to the PROSPECT I trial, the patients will
undergo 3-vessel imaging; only in this trial the NIRS-IVUS
catheter will be used. With the additional information
provided by NIRS the authors plan to build upon the already
known IVUS results (plaque burden associated with higher
event rate) and determine the lipid content of the high-risk
sites [18]. The second trial is called the lipid-rich plaque (LRP)
study. This prospective, observational, case-control study will
enroll 9000 patients undergoing PCI. A registry will be used to
compare the incidence of MACE between the case (large LRP
deﬁned by NIRS-IVUS) and control (small or no LRP detected by
NIRS-IVUS) groups at 2-year follow-up [18].
Conclusion
The above-mentioned facts summarize our knowledge about
the VP and its detection. The advances in the NIRS-IVUSresearch are emphasized as the method bears a great potential
in the search for a lipid-core plaque, a possible clinical
correlate of the VP [33].
It is clear, if we consider the risks and costs, that the
invasive imaging cannot be solely used in the primary
prevention of acute coronary syndrome for the general
population. On the other hand population screening is the
place where detecting a VP might bring the greatest beneﬁts.
Even an angiographically or FFR insigniﬁcant stenosis can
harbor a VP. With this in mind it is clear that there can
potentially be two patients with the same Framingham risk
factors and a similar extent of insigniﬁcant coronary artery
disease that have a completely different risk of MI or sudden
cardiac death. A better risk stratiﬁcation is needed then. This is
where determination of plaques vulnerability may play an
important role. With this additional information the primary
prevention might be tailored for each patient according to his
risk proﬁle. It is probable that some patients may be treated
with a less aggressive protocol, whereas others will have to be
treated more aggressively than today's common practice.
Clearly it would be best to distinguish such patients by some
cheap and non-invasive method. A reliable biomarker seems
to be the best option [35,36], but non-invasive imaging
modalities will surely play their role as well. On the other
hand, it is clear that NIRS and other invasive imaging methods
do not meet the needed criteria. The potential beneﬁts of the
procedures probably do not exceed their risks, especially if we
consider that today the practical outcome of such a procedure
is limited.
It is probable that at ﬁrst the NIRS-IVUS and other invasive
imaging will be used in patients indicated for PCI. In this case
the procedure can be performed without a major increase in
the risks and costs. It has been proven that IVUS-guided DES
implantation is associated with signiﬁcantly lower rates of
adverse clinical events compared with angiography guidance.
The results may be even better with the additional informa-
tion provided by NIRS [37]. The NIRS-IVUS will not only help
with the optimization of the procedure and prevention of
peri-procedural complications, but will also be capable
of identifying lipid-rich non-culprit lesions in other regions
of the coronary arterial bed. The knowledge about the
presence of such VP can then modify the following secondary
prevention strategy. For example, the pharmaceutical treat-
ment may be tailored for such patients as there already exists
evidence that high-dose statin therapy has the potential of
lowering the lipid content of a lesion and possibly stabilizing a
VP [34].
The article shows evidence that the above-mentioned
imaging methods have a great potential for detecting a VP.
Clearly large prospective studies are needed to establish the
optimal approach in the ultimate quest of detecting a VP prior
to its rupture and possibly developing an effective treatment
strategy for its subsequent stabilization thus actually pre-
venting coronary events from happening.
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